CONFIDENTIAL

COLARIS ®
MYH Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD **Comprehensive Medical Center** **1100 Grand Ave** **Away, GA 12345**	Specimen: **Blood** Draw date: **Aug 01, 2010** Accession date: **Aug 02, 2010** Report Date: **Aug 12, 2010**	Name: **Doe, Jane** Date of Birth: **April 1, 1492** Patient ID: **000000** Gender: **Female** Accession #: **00000000-BLD** Requisition #: **000000**

Test Results and Interpretation

POSITIVE FOR TWO COPIES OF AN MYH MUTATION
COLORECTAL POLYPOSIS AND CANCER RISK MARKEDLY INCREASED

Test Performed:	Result:	Interpretation:
MYH sequencing	G382D (1145G>A), 2 copies	**Deleterious**

Analysis consists of sequencing of all exons and immediately adjacent intronic regions of the MYH gene and large rearrangement testing of MYH by microarray comparative genomic hybridization (microarray CGH). The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

This analysis detected two (homozygous) copies of the germline MYH mutation, G382D (1145G>A). MYH-associated polyposis and colorectal cancer is a recessive disease. Since two copies of an MYH mutation are present, this individual is at increased risk for MYH-associated polyposis and colorectal cancer. Although the exact cancer risk associated with these specific mutations is unknown, the presence of two deleterious MYH mutations has been estimated to cause up to an 80% lifetime risk of developing colorectal cancer (Cancer Epidemiol Biomarkers Prev 2006;15(2):312-4). Full siblings of this individual have at least a 25% chance of having inherited both copies of this MYH mutation. Genetic testing should be considered in these individuals.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.